Intellia Therapeutics (38I) Stock Forecast & Price Target

Compare

13 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

38I Analyst Ratings

Moderate Buy

8 Buy

8 Hold

1 Sell

Based on 17 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

38I Stock 12 Month Forecast

Average Price Target

€18.01

▲(68.17% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is €18.01 with a high forecast of €41.93 and a low forecast of €6.11. The average price target represents a 68.17% change from the last price of €10.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","42":"€42","14.25":"€14.25","23.5":"€23.5","32.75":"€32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41.92560816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€41.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.0105425054,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.11415119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14.25,23.5,32.75,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,14.421969858461539,16.71393971692308,19.005909575384617,21.297879433846155,23.589849292307694,25.881819150769232,28.173789009230774,30.46575886769231,32.75772872615385,35.049698584615385,37.34166844307693,39.63363830153847,{"y":41.92560816,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,12.582349423492309,13.034698846984616,13.487048270476924,13.939397693969232,14.39174711746154,14.844096540953846,15.296445964446153,15.748795387938461,16.20114481143077,16.653494234923077,17.105843658415385,17.558193081907692,{"y":18.0105425054,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,11.66724239923077,11.20448479846154,10.741727197692308,10.278969596923078,9.816211996153847,9.353454395384617,8.890696794615385,8.427939193846154,7.965181593076924,7.502423992307693,7.0396663915384625,6.576908790769231,{"y":6.11415119,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€41.93

Average Price Target€18.01

Lowest Price Target€6.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

€25.1

Buy

134.38%

Upside

Upgraded

03/04/26

Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)

Whitney Ijem

Canaccord Genuity

€46.74→€41.55

Buy

287.94%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target lowered to $48 from $54 at CanaccordIntellia Therapeutics price target lowered to $48 from $54 at Canaccord

Silvan Tuerkcan

Citizens JMP

€18.18→€24.24

Buy

126.30%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target raised to $28 from $21 at CitizensIntellia Therapeutics price target raised to $28 from $21 at Citizens

Yanan Zhu

Wells Fargo

€10.39→€12.98

Hold

21.23%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target raised to $15 from $12 at Wells FargoIntellia Therapeutics price target raised to $15 from $12 at Wells Fargo

Mitchell Kapoor

H.C. Wainwright

€21.64→€25.97

Buy

142.47%

Upside

Reiterated

03/03/26

H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€10.39

Hold

-3.01%

Downside

Reiterated

03/03/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Myles Minter

William Blair

―

Buy

―

Upgraded

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)

Geulah Livshits

Chardan Capital

€23.37

Buy

118.22%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Terence Flynn

Morgan Stanley

€9.52

Hold

-11.10%

Downside

Reiterated

03/02/26

Balancing Reduced Regulatory Risk and Ongoing Development Uncertainty: Rationale for Maintaining a Hold Rating

Alec Stranahan

Bank of America Securities

€14.72→€16.45

Hold

53.56%

Upside

Reiterated

03/02/26

Bank of America Securities Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)

Brian Cheng

J.P. Morgan

―

Sell

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Luca Issi

RBC Capital

€7.79→€12.98

Hold

21.23%

Upside

Reiterated

03/02/26

RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

Jonathan Miller

Evercore ISI

€6.92→€12.12

Hold

13.15%

Upside

Reiterated

01/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Viridian Therapeutics (NASDAQ: VRDN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

€25.1

Buy

134.38%

Upside

Upgraded

03/04/26

Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)

Whitney Ijem

Canaccord Genuity

€46.74→€41.55

Buy

287.94%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target lowered to $48 from $54 at CanaccordIntellia Therapeutics price target lowered to $48 from $54 at Canaccord

Silvan Tuerkcan

Citizens JMP

€18.18→€24.24

Buy

126.30%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target raised to $28 from $21 at CitizensIntellia Therapeutics price target raised to $28 from $21 at Citizens

Yanan Zhu

Wells Fargo

€10.39→€12.98

Hold

21.23%

Upside

Reiterated

03/03/26

Intellia Therapeutics price target raised to $15 from $12 at Wells FargoIntellia Therapeutics price target raised to $15 from $12 at Wells Fargo

Mitchell Kapoor

H.C. Wainwright

€21.64→€25.97

Buy

142.47%

Upside

Reiterated

03/03/26

H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€10.39

Hold

-3.01%

Downside

Reiterated

03/03/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Myles Minter

William Blair

―

Buy

―

Upgraded

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)

Geulah Livshits

Chardan Capital

€23.37

Buy

118.22%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Terence Flynn

Morgan Stanley

€9.52

Hold

-11.10%

Downside

Reiterated

03/02/26

Balancing Reduced Regulatory Risk and Ongoing Development Uncertainty: Rationale for Maintaining a Hold Rating

Alec Stranahan

Bank of America Securities

€14.72→€16.45

Hold

53.56%

Upside

Reiterated

03/02/26

Bank of America Securities Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)

Brian Cheng

J.P. Morgan

―

Sell

―

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Luca Issi

RBC Capital

€7.79→€12.98

Hold

21.23%

Upside

Reiterated

03/02/26

RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)

Jonathan Miller

Evercore ISI

€6.92→€12.12

Hold

13.15%

Upside

Reiterated

01/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Viridian Therapeutics (NASDAQ: VRDN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months

xxx

Success Rate

14/35 ratings generated profit

Average Return

+13.88%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +13.88% per trade.

1 Year

Gena WangBarclays

Success Rate

10/26 ratings generated profit

Average Return

-12.89%

reiterated a buy rating 4 months ago

Copying Gena Wang's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -12.89% per trade.

2 Years

xxx

Success Rate

5/16 ratings generated profit

Average Return

-23.99%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.25% of your transactions generating a profit, with an average return of -23.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

38I Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 38I has received 14 Buy Ratings, 69 Hold Ratings, and 7 Sell Ratings. 38I average Analyst price target in the past 3 months is 18.01.

Each month's total comprises the sum of three months' worth of ratings.

38I Financial Forecast

38I Earnings Forecast

Next quarter’s earnings estimate for 38I is -€0.80 with a range of -€0.96 to -€0.63. The previous quarter’s EPS was -€0.72. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Sales Forecast

Next quarter’s sales forecast for 38I is €11.81M with a range of €0.00 to €20.09M. The previous quarter’s sales results were €20.03M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Stock Forecast FAQ

What is DE:38I’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 18.01.

What is DE:38I’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics has 68.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Intellia Therapeutics a Buy, Sell or Hold?

Intellia Therapeutics has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 8 hold ratings and 1 sell ratings.

What is Intellia Therapeutics’s share price target?

The average share price target for Intellia Therapeutics is 18.01. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €41.93 ,and the lowest forecast is €6.11. The average share price target represents 68.17% Increase from the current price of €10.71.

What do analysts say about Intellia Therapeutics?

Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Intellia Therapeutics?

To buy shares of DE:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Intellia Therapeutics (38I) Stock Forecast & Price Target

38I Analyst Ratings

38I Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

38I Analyst Recommendation Trends

38I Financial Forecast

38I Earnings Forecast

38I Sales Forecast

38I Stock Forecast FAQ

Detailed List of Analyst Forecasts